Oncternal Therapeutics is a clinical-stage oncology company developing targeted therapies for hematological malignancies and prostate cancer by exploring untapped biological pathways involved in cancer progression. The company addresses the critical unmet medical needs of patients with these cancers through its diverse pipeline of treatment modalities.
Funding
$86.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many hematological malignancies and prostate cancers have limited effective treatment options, resulting in significant unmet medical needs for patients facing these diagnoses. Current therapies may not target the specific biological pathways driving cancer progression, leading to suboptimal outcomes.
Solution
Oncternal Therapeutics is a clinical-stage company focused on developing targeted therapies for hematological malignancies and prostate cancer. The company's scientific approach centers on exploring untapped biological pathways involved in cancer generation or progression to create novel oncology therapies. Oncternal is developing a diverse pipeline of treatments across multiple modalities.
Target Audience
The company focuses on patients with hematological malignancies and prostate cancer.
Features
- Developing treatments for hematological malignancies
- Developing treatments for prostate cancer
- Pipeline includes ONCT-808
- Pipeline includes ONCT-534
- Pipeline includes Zilovertamab